Samuel D. Isaly
Member since: Aug '04
Portfolio Manager at
Eaton Vance Worldwide

Latest Top Picks

Growing very well. Their biggest drug is for high blood pressure but also have a good product line for cancer treatment. Not many patent exposures in the near-term.
Lots of new products. Rapid profit growth.
A very rapidly growing company. Earnings per share growth is in excess of 20% yearly. PE ratio barely more than that.
Has a low market cap. Have a drug that extends life in lung cancer which should be approved around the turn of the year.